Le Lézard
Classified in: Health
Subjects: SVY, TRI

Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research


PARSIPPANY, N.J., Sept. 27, 2017 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced the development and validation of the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical trials. The new IGA scale is being presented at the 47th Annual ESDR Meeting 2017 held at the Salzburg Congress Centre in Salzburg, Austria September 27-30th, 2017.

The five-point IGA scale for overall clinical assessment defines EBS-involved skin as Clear, Almost Clear, Mild, Moderate, and Severe, based on the presence or absence of blisters and factors including blister size, erosions, crusting and erythema. The IGA scale will be used to evaluate the safety and efficacy of diacerein 1% ointment, an investigational topical being developed by CCP for the treatment of EBS, in the ongoing Phase 2/3 DELIVERS study.

Alain Hovnanian, MD, PhD, department of genetics at the University Paris Descartes in Paris, France, will present the IGA scale during a special poster walk session, "Clinical Outcomes 3: Bullous diseases and other entities," on Saturday, September 30th, from 10:30-11:30am CEST.

"We have standard instruments in place for evaluating therapies for epidermolysis bullosa in general, but until now no such instrument has been validated for evaluating the severity of EBS lesions specifically," said Dr. Hovnanian. "This first-of-its-kind IGA scale will serve an important role in advancing clinical research and determining the efficacy of potential therapies for the most common form of epidermolysis bullosa."

In a separate presentation that has also been selected for the "Clinical Outcomes 3: Bullous diseases and other entities" poster walk session, Michael Ablinger, MSc, scientific associate at the EB House Austria, will discuss results from a proof-of-concept study evaluating the safety of diacerein 1% ointment topically applied in generalized-severe EBS.

In the study, researchers analyzed the metabolization of diacerein 1 % ointment both in vitro and in vivo. A Franz diffusion cell setup demonstrated complete conversion into rhein within the skin, and bio-transformation into rhein was also observed in patients upon topical application. Treatment of 3% of the body surface for four weeks resulted in systemic rhein levels that were approximately 150-fold lower than levels detected 24 hours after single-dose oral intake.

"Our results demonstrate that the prodrug diacerein is converted into its active form rhein within the skin," said Ablinger. "The process allows for an anti-inflammatory effect in the skin of EBS patients."

For more information about the 47th Annual ESDR Meeting 2017, visit http://www.esdr2017.org.

About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP) is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of debilitating dermatologic and head and neck conditions with high unmet needs. CCP is working with TWi Biotechnology, Inc. based in Taipei, Taiwan for manufacture and development of CCP-020. For more information, please visit www.castlecreekpharma.com.

Media contact:

Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

SOURCE Castle Creek Pharmaceuticals


These press releases may also interest you

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...

at 11:00
Eagle Hill Consulting has earned another top workplace award, this time selected by The Washington Business Journal as a 2024 Best Places to Work in the extra-large sized company category. Eagle Hill also has earned multiple best workplace awards...

at 11:00
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura,...

at 10:53
A one-of-a-kind healthcare collaborative, the Center for Better Aging (CBA) located at St. Bernard Hospital, opens in July with a health equity mandate to serve the growing 50+ population on Chicago's Greater South Side. ...

at 10:46
FullCare Medical has launched a new medical garment production facility in Tatu City, the 5,000-acre mixed-use Special Economic Zone (SEZ) in Kenya....



News published on and distributed by: